Gregory Lovallo, MD
Urology · Maywood, NJNPI 1467515775
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.6% of the total across 167 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 41 manufacturers, the largest accounting for just 13.1% — the pattern of someone who eats at a lot of different presentations.
Across 167 payments — averaging $37.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Royal Biologics, Inc.$820
- Johnson & Johnson$778
- Kerecis Limited$602
- Procept Biorobotics Corporation$537
- Boston Scientific$426
- Astellas Pharma US Inc$377
- plus $3K from 35 others
Across 5 payments — averaging $20,000 each. An ownership or investment interest held by the physician or an immediate family member.
- New Wave Endo-surgical Corp.$100K
What the payments were for
- Travel & lodging$1633%
- Food & beverage$5,99696%
- Education$1152%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerecis Omega3 Marigen$1,539
- Cryo-Cord$707
- STRATAFIX$561
- Kerecis Omega3 SurgiClose$422
- Echelon Flex$319
- AquaBeam Robotic System$273
- AQUABEAM SYSTEM$165
- FOCAL ONE$158
- SURGICEL NU-KNIT$154
- Kerecis Omega3 GraftGuide$148
- Tulsa-Pro$145
- ALTIS$136
- AIRSEAL$130
- VISTASEAL Fibrin Sealant (Human)$125
- ECHELON ENDOPATH$125
- DERMABOND PRINEO$125
- GENERAL KIDNEY STONE DISEASE$120
- VISTASEAL$117
- Barrigel$107
How this compares
$6,273 in reported general payments places this provider in the 75th percentile of 401 urology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 247 | $203,812 |
| GemtesaVibegron | 118 | $98,519 |
| Dutasteride-TamsulosinDutasteride/Tamsulosin Hcl | 93 | $19,230 |
| Tamsulosin Hcl | 592 | $10,877 |
| Finasteride | 422 | $7,903 |
| Solifenacin Succinate | 102 | $5,224 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 62 | $5,196 |
| Methenamine Hippurate | 54 | $4,895 |
| Silodosin | 40 | $3,696 |
| Tadalafil | 52 | $3,069 |
| NitrofurantoinNitrofurantoin Macrocrystal | 48 | $2,209 |
| Potassium Citrate ErPotassium Citrate | 24 | $2,025 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 54 | $1,873 |
| Testosterone | 38 | $1,810 |
| Dutasteride | 52 | $1,515 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $377 | $203,812247 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $19 | $98,519118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 401 urology providers in New Jersey.
Other urology in Maywood
- Mutahar AhmedMaywood$414K
- Michael EspositoMaywood$28K
- Michael StifelmanHackensack$1.4M
- Gordon BrownCherry Hill$1.3M
- Thomas MuellerLinwood$1.1M
- David SussmanLinwood$802K
- Michael IngberDenville$530K
- Ravi MunverHackensack$529K
- Grannum SantBridgewater$487K
- Kevin GioiaRumson$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.